The
formation of microbial biofilms is acknowledged as a major
virulence factor in a range of persistent local infections. Failures
to remove biofilms with antibiotics foster the emergence of antibiotic-resistant
bacteria and result in chronic infections. As a result, the construction
of effective biofilm-inhibiting and biofilm-eradicating chemicals
is urgently required. Herein, we designed a water-soluble probe APDIS for membrane-active fluorescence and broad-spectrum
antimicrobial actions, particularly against methicillin-resistant Staphylococcus aureus (MRSA), which shows multidrug
resistance. In vitro and in vivo experiments demonstrate its high antibacterial effects comparable
to vancomycin. Furthermore, it inhibits biofilm formation by effectively
killing planktonic bacteria at low inhibitory concentrations, without
toxicity to mammalian cells. More importantly, this probe can efficiently
penetrate through biofilm barriers and exterminate bacteria that are
enclosed within biofilms and startle existing biofilms. In the mouse
model of implant-related biofilm infections, this probe exhibits strong
antibiofilm activity against MRSA biofilms, thus providing a novel
theranostic strategy to disrupt biofilms in vivo effectively.
Our results indicate that this probe has the potential to be used
for the development of a combinatorial theranostic platform with synergistic
enhanced effects for the treatment of multidrug-resistant bacterial
infections and antibiofilm medications.